Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Overview

Basilea is providing expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib is ongoing.

Full Title of Study: “Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations”

Study Type

  • Study Type: Expanded Access

Interventions

  • Drug: derazantinib
    • derazantinib will be administered orally

Participating in This Clinical Trial

Inclusion Criteria

  • all other treatment options have been exhausted
  • patient is ineligible for any ongoing trials or is geographically inaccessible to trials including an ongoing trial with derazantinib
  • there is reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product
  • patient is willing and able to provide written informed consent
  • if applicable, regulatory approval by the appropriate jurisdiction is obtained

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Basilea Pharmaceutica
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Frédérique Cantero, MD, +41768302499, frederique.cantero@basilea.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.